In view of the above experimental results, although the mechanism of the effect of the cGAS–STING pathway on fatty liver (including NAFLD and ALD) is not fully elucidated, it is possible to suggest that the cGAS–STING pathway could be a potential therapeutic target for the treatment of fatty liver. The gene discussed is STING1; the disease is metabolic dysfunction-associated steatotic liver disease.